SCHEMBL24529621

SCHEMBL24529621

CC(=O)N[C@@H]1C(O)C[C@](OC2C(O)[C@H](O[C@@H]3C(CO)O[C@@H](O)C(O)C3O)OC(CO)[C@@H]2O)(C(=O)O)OC1[C@H](O)[C@H](O)CO

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SIGLEC7 Q9Y286 6/20 0.70
▸ MAG P20916 9/20 0.67
▸ SELP P16109 2/20 0.66
▸ SELL P14151 1/20 0.66
▸ SELE P16581 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390469 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL25658073 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL29376404 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL30001490 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL14362211 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL19922285 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL29357459 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL4312517 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL20885234 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE
SCHEMBL25662685 1.00 SIGLEC7 (0.70) SIGLEC7MAGSELPSELLSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216406-A1 METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL INTRINSIC MEDICINE INC (US) 2024-07-04 — — US disclosed
US-20220218727-A1 METHODS AND COMPOSITIONS OF SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL INTRINSIC MEDICINE, INC. 2022-07-14 — — US disclosed
US-20220193099-A1 IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN TARGET CAPITAL 4 LLC 2022-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193099-A1 IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN FUT6, CSGALNACT1, FUT5 SIGLEC7 19/4885MAG 24/4885SELP 168/4885
US-20240216406-A1 METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL FUT6, FUT5, FUCA2 SIGLEC7 195/4885MAG 489/4885SELP 500/4885
US-20220218727-A1 METHODS AND COMPOSITIONS OF SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL FUT6, FUT5, FUCA2 SIGLEC7 195/4885MAG 525/4885SELP 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback